**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 46717

**Manuscript Type:** META-ANALYSIS

**Efficacy of hybrid minimally invasive esophagectomy *vs* open esophagectomy for esophageal cancer: A meta-analysis**

Yang J *et al.* HMIE *vs* OE for esophageal cancer

Jiao Yang, Ling Chen, Ke Ge, Jian-Le Yang

**Jiao Yang, Ling Chen, Ke Ge, Jian-Le Yang,**Department of Infectious Diseases, Zhejiang Hospital, 12 Lingyin Road, Hangzhou 310013, Zhejiang Province, China

**ORCID number:** Jiao Yang (0000-0002-6325-6455); Ling Chen (0000-0002-2132-8043); Ke Ge (0000-0002-4561-3906); Jian-Le Yang (0000-0001-7574-6702).

**Author contributions:** Yang J contributed to idea conception, literature search, data extraction, and manuscript writing and approval; Chen L contributed to data extraction, data confirmation, and manuscript writing and approval; Ge K and Yang JL contributed to data confirmation and manuscript writing and approval.

**Conflict-of-interest statement:** None to declare.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Jiao Yang, MD, Doctor,** Department of Infectious Diseases, Zhejiang Hospital, 12 Lingyin Road, Hangzhou 310000, Zhejiang Province, China. yangjiao19890912@163.com

**Telephone:** +86-13516812609

**Fax:** +86-571-87980175

**Received:** February 25, 2019

**Peer-review started:** February 26, 2019

**First decision:** April 16, 2019

**Revised:** May 13, 2019

**Accepted:** August 18, 2019

**Article in press:** August 18, 2019

**Published online:** November 15, 2019

**Abstract**

***BACKGROUND***

The first line treatment regimen for esophageal cancer is still surgical resection and the choice of surgical scheme depends on surgeon. Now the efficacy comparison of hybrid minimally invasive esophagectomy (HMIE) and open esophagectomy (OE) is still controversial.

***AIM***

To compare the perioperative and postoperative outcomes of HMIE and OE in patients with esophageal cancer.

***METHODS***

PubMed, EMBASE, and Cochrane Library databases were searched for related articles. The odds ratio (OR)or standard mean difference (SMD) with a 95% confidence interval (CI) was used to evaluate the effectiveness of HMIE and OE.

***RESULTS***

Seventeen studies including a total of 2397 patients were selected. HMIE was significantly associated with less blood loss (SMD = -0.43, 95%CI: -0.66, -0.20; *P* = 0.0002) and lower incidence of pulmonary complications (OR = 0.72, 95%CI: 0.57, 0.90; *P* = 0.004). No significant differences were seen in the lymph node yield (SMD = 0.11, 95%CI: -0.08, 0.30; *P* = 0.26), operation time (SMD = 0.24, 95%CI: -0.14, 0.61; *P* = 0.22), total complications rate (OR = 0.68, 95%CI: 0.46, 0.99; *P* = 0.05), cardiac complication rate (OR = 0.91, 95%CI: 0.62, 1.34; *P* = 0.64), anastomotic leak rate (OR = 0.95, 95%CI: 0.67, 1.35; *P* = 0.78), duration of intensive care unit stay (SMD = -0.01, 95%CI: -0.21, 0.19; *P* = 0.93), duration of hospital stay (SMD = -0.13, 95%CI: -0.28, 0.01; *P* = 0.08), and total mortality rates (OR = 0.70, 95%CI: 0.47, 1.06; *P* = 0.09) between the two treatment groups.

***CONCLUSION***

Compared with the OE, HMIE shows less blood loss and pulmonary complications. However, further studies are necessary to evaluate the long-term oncologic outcomes of HMIE.

**Key words:** Hybrid minimally invasive esophagectomy; Open esophagectomy; Esophageal cancer

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In this meta-analysis, hybrid minimally invasive esophagectomy (HMIE) was found to be associated with less blood loss and lower incidence of pulmonary complications compared to conventional open esophagectomy (OE). In the subgroup analysis, patients with HMIE using laparoscopic gastric mobilization-thoracotomy presented less blood loss, shorter hospital stay, lower incidence of total and pulmonary complications than those with OE. No significant difference was observed between the two groups in mortality. In conclusion, our study is the first meta-analysis confirming the priority of HMIE to OE.

**Citation:** Yang J, Chen L, Ge K, Yang JL. Efficacy of hybrid minimally invasive esophagectomy *vs* open esophagectomy for esophageal cancer: A meta-analysis. *World J Gastrointest Oncol* 2019; 11(11): 1081-1091

URL: https://www.wjgnet.com/1948-5204/full/v11/i11/1081.htm

DOI: <https://dx.doi.org/10.4251/wjgo.v11.i11.1081>

**INTRODUCTION**

Esophageal cancer is the eighth most common cancer worldwide, with nearly 17000 newly diagnosed cases and 15910 deaths recorded annually in the United States alone[1]. Despite early diagnosis and advanced therapeutic modalities, including surgical resection, radiotherapy, and chemotherapy, the 5-year overall survival rate is a dismal 15% to 20%[2]. Esophageal resection remains the major curative and palliative option for dysphagia. For middle- and lower-third esophageal cancer, the abdominal and right thoracic approach is selected due to good loco-regional control. However, post-esophagectomy morbidity and mortality rates are 30%-50% and 2%-10%, respectively[3], mainly due to endocrinal and metabolic changes. The most frequent complications of esophagectomy are the major pulmonary complications (MPPCs), such as pneumonia and acute respiratory distress syndrome. Almost 50% of the postoperative deaths are attributed to MPPCs, which are indicative of poor prognosis.

Cuschieri *et al*[4] introduced endoscopic esophagectomy in 1992, which was followed by the development of minimally invasive esophagectomy (MIE), which uses a thoraco-abdominal approach and a combination of laparoscopy, thoracoscopy, and transhiatal laparoscopy. MIE can reduce surgical stress response, decrease blood loss, shorten hospital stay, and lower the incidence of complications[5-7]. However, only a few randomized controlled trials (RCTs) and low-quality meta-analysis have evaluated its clinical outcomes, in terms of tumor and lymph node clearance, and the safety profile. Hybrid MIE (HMIE) is performed using an Ivor-Lewis procedure, *via* a thoracoscopic-laparotomy and laparoscopic gastric mobilization-thoracotomy, for tumors of the mid-lower esophagus. A three stage McKeown’s procedure, with an additional left cervical incision, has been developed for the upper third of the esophagus. Open esophagectomy is performed by starting with an open right thoracotomy to mobilize the esophagus, followed by an open laparotomy to mobilize and pull the stomach to the neck for anastomosis. Therefore, HMIE may improve perioperative outcomes. The aim of this study was to compare the efficacy of open esophagectomy (OE) and HMIE in esophageal cancer patients.

**MATERIALS AND METHODS**

***Literature search***

PubMed, EMBASE, and Cochrane Library databases were searched for studies published till February 1, 2019 using the following key words: Open esophagectomy, HMIE, minimally invasive esophagectomy, and esophageal cancer. In addition, the reference lists of the eligible studies were manually searched to include additional studies.

***Study selection***

The inclusion criteria for the studies were as follows: (1) RCTs and non-RCTs; (2) including patients with esophageal cancer; (3) comparing the outcomes of OE and HMIE; and (4) evaluating intraoperative outcomes and postoperative outcomesof both modalities. The exclusion criteria were: (1) in languages other than English; (2) lacking comparison of OE and HMIE; and (3) case reports and duplicate publications.

***Data extraction***

Two authors evaluated the titles, abstracts, and the reference lists of the publications, and independently extracted the data of intraoperative outcomes (lymph node yield, blood loss, and operative time) and postoperative outcomes (the rates of total complications, pulmonary complications, cardiac complications, and anastomotic leak, the duration of intensive care unit (ICU) stay and hospital stay, and total 30-d and 90-d mortality). Any disagreements were resolved by discussion with a third investigator. For case-control studies, the Newcastle-Ottawa Quality Assessment Scale was used to assess the quality of the eligible studies, and those with a score ≥ 6 were included. Quality of RCTs was evaluated using the risk bias of Cochrane Collaboration tool.

***Statistical analysis***

All analyses were performed with the RveMan5.3 tool (Nordic Cochrane Centre, Cochrane Collaboration). Study heterogeneity was assessed using *χ*2 and Ι2 tests. A fixed-effects model was used when Ι2 was < 50% or *P* > 0.1, indicating no significant heterogeneity amongst the studies, and a random-effects model was used when Ι2 was > 50% or *P* < 0.1.Odds ratio (OR), standard mean difference (SMD), and 95% confidence interval (CI) were used as effect measurements, and *P* < 0.05 was considered statistically significant. Publication bias was evaluated by funnel plots and sensitivity analysis was applied to assess the stability of results.

**RESULTS**

***Characteristics of selected studies***

A total of 17 studies, including 2 RCTs[8,9] and 15 case-control studies[10-24], were eligible for the meta-analysis. The studies included 2397 esophageal carcinoma patients, of which 1170 received HMIE and 1227 underwent OE. The detailed search strategy is shown in Figure 1. The baseline characteristics and quality of the included studies are summarized in Tables 1, 2, 3, and 4.

***Intraoperative outcomes***

**Lymph node yield:** Nine studies reported the lymph node yield, with no significant difference between the HMIE with different approaches and OE groups (SMD = 0.11; 95%CI: -0.08, 0.30; *P* = 0.26; Table 5). Since significant heterogeneity (*I*2 = 65% and *P* = 0.004) was observed amongst the studies, a random-effects model was utilized. Then, subgroup analysis was used to compare HMIE with laparoscopy and thoracotomy and OE. Patients with laparoscopy and thoracotomy (HMIE) presented no more lymph node yield compared to those with OE (SMD = 0.19; 95%CI: -0.00, 0.37; *P* = 0.05; Table 5).

**Blood loss:** Six trials evaluated blood loss, which was also analyzed using the random-effects model due to significant heterogeneity (*I*2 = 58% and *P* = 0.04). HMIE with different strategies resulted in significantly lower blood loss compared to OE (SMD = -0.43; 95%CI: -0.66, -0.20; *P* = 0.0002; Table 5).In the subgroup analysis, HMIE using laparoscopy and thoracotomy showed priority to OE in decreasing the blood loss (SMD = -0.51; 95%CI: -0.74, -0.27; *P* < 0.0001; Table 5)

**Operative time:** Twelve studies involving 1630 patients recorded the operative time, and displayed significant heterogeneity in the outcome (*I*2 = 92% and *P* < 0.00001). However, HMIE with different approaches or HMIE with laparoscopy and thoracotomy did not significantly decrease the duration of operation (SMD = 0.24; 95%CI: -0.14, 0.61; *P* = 0.22 and SMD = 0.10; 95%CI: -0.33, 0.52; *P* = 0.65, respectively; Table 5).

***Postoperative outcomes***

**Complications:** Fourteen trials provided data of the total complications, and showed no significant differences between the HMIE with different approaches group and OE group (OR = 0.68; 95%CI: 0.46, 0.99; *P* = 0.05; Table 6). However, patients with HMIE using laparoscopy and thoracotomy presented less total complications than those with OE (OR = 0.62; 95%CI: 0.41, 0.94; *P* = 0.02; Table 6). Total HMIE and HMIE with laparoscopy and thoracotomy were associated with less pulmonary complications than OE (OR = 0.72; 95%CI: 0.57, 0.90; *P* = 0.004 and OR = 0.69; 95%CI: 0.53, 0.90; *P* = 0.005, respectively; Table 6), whereas the incidences of cardiac complications (OR = 0.91; 95%CI: 0.62, 1.34; *P* = 0.64 and OR = 0.97; 95%CI: 0.65, 1.43; *P* = 0.86, respectively; Table 6) and anastomotic leak (OR = 0.95; 95%CI: 0.67, 1.35; *P* = 0.78 and OR = 0.99; 95%CI: 0.67, 1.46; *P* = 0.96, respectively; Table 6) were similar.

**Hospital and ICU stays:** Thirteen studies reported duration of hospital stay with significant heterogeneity (*I*2 = 57% and *P* = 0.006), and total HMIE was not associated with significantly reduced duration of hospital stay (SMD = -0.13; 95%CI: -0.28, 0.01; *P* = 0.08; Table 6). However, shorter hospital stay showed in patients with HMIE using laparoscopy and thoracotomy than those with OE (SMD = -0.37; 95%CI: -0.64, -0.09; *P* = 0.009; Table 6).

In addition, the duration of ICU stay was similar in total HMIE or HMIE with laparoscopy and thoracotomy group and OE group (SMD = -0.01; 95%CI: -0.21, 0.19; *P* = 0.93 and SMD = -0.05; 95%CI: -0.37, 0.27; *P* = 0.76, respectively; Table 6).

**Mortality:** No significant heterogeneity was detected amongst the studies reporting the total, 30-d, and 90-d mortality rates, which were similar in total HMIE or HMIE with laparoscopy and thoracotomy group and OE group (total mortality: OR = 0.70, 95%CI: 0.47, 1.06, *P* = 0.09 and OR = 0.65, 95%CI: 0.4, 1.07, *P* = 0.09, respectively; 30-d mortality: OR = 1.00, 95%CI: 0.45, 2.23, *P* = 0.99 and OR = 1.10, 95%CI: 0.47, 2.59, *P* = 0.82, respectively; 90-d mortality: OR = 0.80, 95%CI: 0.43, 1.48, *P* = 0.47 and OR = 0.80, 95%CI: 0.43, 1.48, *P* = 0.47, respectively; Table 6).

**Publication bias:** Publication bias was evaluated for the outcomes of pulmonary complications, cardiac complications, anastomotic leak, and total mortality and none was detected (Figure 2).

***Sensitivity analysis***

We removed any single trial, chose different effect models, and conducted subgroup analysis, and the outcomes presented no significant changes, suggesting that the results were stable.

**DISCUSSION**

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Surgical resection is the first line of treatment, and includes OE, total MIE, and HMIE. Depending on the surgeon and the hospital, the choice and sequence of surgical approaches differ significantly (transthoracic *vs* transhiatal, intrathoracic *vs* cervical anastomosis, and the degree of lymphadenectomy). OE is associated with a significantly higher risk of surgical trauma, as well as higher morbidity and mortality compared to other surgeries[25]. Sunpaweravong *et al*[25] conducted a meta-analysis to compare the efficacy of OE and MIE, and found that MIE resulted in fewer perioperative complications and less mortality. In addition, patients with MIE had better quality of life scores compared to those with OE in the global health, pain, and physical activity domains[26]. Therefore, total MIE would be the ideal choice. But the technical difficulties, the long learning curve, and low reproducibility of the anastomosis limit its use. HMIE has a shorter learning curve while sharing the advantages of MIE. The transition from OE to HMIE may be acceptable. The above information of MIE does not distinguish between the total MIE and HMIE approaches, so whether HMIE is prior to OE is still controversial. In this meta-analysis, we first compared the intraoperative and postoperative outcomes of HMIE and OE in patients with esophageal cancer.

Many studies show that radical lymph node resection and greater extent of lymphadenectomy are closely associated with higher survival rates[27-30]. In this study, there was no significant difference in terms of the number of harvested lymph nodes between total HMIE and OE groups, which is consistent with a previous RCT[8]. But there was a trend for patients with HMIE using laparoscopy and thoracotomy with a high rate of lymphadenectomy. Some studies once reported a higher or lower number of lymph nodes harvested in MIE group[31,32]. Those discrepancies may be explained by the inconsistency of Current Procedure Terminology codes reported by the operating surgeons.

Smithers *et al*[12] reported that patients who underwent HMIE had less blood loss than those undergoing OE, while Yanasoot *et al*[24] showed no significant difference. In our meta-analysis also, the total HMIE group and the HMIE with laparoscopy and thoracotomy group had less blood loss, which could be attributed to the relatively minimal trauma in HMIE.

Studies also report a longer operative duration of MIE compared to OE[33-35], which can result in atelectasis and pneumonia. In our meta-analysis, the operative time was similar for both surgeries.

Postoperative complications, especially pulmonary complications, significantly influence the survival of esophageal cancer patients. The incidences of total complications in patients with total HMIE and OE were 50.2% and 60.1%, respectively, although the lower occurrence after HMIE was not statistically significant. In the subgroup analysis, HMIE with laparoscopy and thoracotomy could largely lower the incidence of total complications than OE (46.55% *vs* 57.74%). The TIME trial showed that MIE resulted in a 70% lower incidence of pneumonia at 2 weeks post-surgery compared to OE[36], which is consistent with our slightly higher incidence in OE compared to total HMIE or HMIE with laparoscopy and thoracotomy (25.37% *vs* 32.08% or 24.59% *vs* 31.23%). In contrast, the incidence of cardiac complications and anastomotic leak was not affected by the type of surgery.

Less pulmonary complications in the total HMIE group did not translate into a significant reduction in the duration of ICU and hospital stay. But HMIE with laparoscopy and thoracotomy presented a more reduction in the duration of hospital stay on the basis of its lower total complications and pulmonary complications.

Some studies indicate that the prolonged survival associated with HMIE is due to the lower incidence of postoperative complications[37-39]. In our meta-analysis, the overall, 30-d, and 90-d mortality rates in the total HMIE group were 4.16%, 2.52%, and 4.00%, respectively *vs* 6.02%, 2.40%, and 4.70% in the OE group, indicating a lack of short-term survival benefit with total HMIE. Patients with HMIE using laparoscopy and thoracotomy presented no priority in short-term survival compared to those with OE. Wang *et al* reported that 6-year overall survival and disease-free survival were 44.7% and 46.1%, respectively, for MIE, indicating that MIE is safe[40]. A score-matched study showed that the 2-year overall survival rates based on same pathologic stage were similar between MIE and OE[41]. But further studies are still needed to clarify the long-term survival outcomes.

Our study has several limitations that need to be addressed. First, only two out of the 17 studies were RCTs and the remaining were case-control studies which might have influenced the reliability of the results, although they were consistent with that of one eligible RCT. Second, the studies had variable follow-up duration, neoadjuvant chemoradiotherapy, operating surgeons, pathological stages, histological types and location of the tumor, and baseline characteristics of the recruited population. Third, the meta-analysis did not compare the long-term oncological outcomes between HMIE and OE. Last but not the least, we made subgroup analysis between HMIE with laparoscopy and thoracotomy and OE group. But the information associated with HMIE using thoracoscopic-laparotomy approach is little and ambiguous. Therefore, the real impact of laparoscopy compared to thoracoscopy is unclear, and data that can confirm which part of esophagectomy would play an important role in MIE is lacking.

Taken together, HMIE, especially HMIE with laparoscopy and thoracotomy, has the advantages of reduced blood loss and lower incidence of pulmonary complications compared to OE for patients with esophageal cancer. However, there is no significant difference in overall survival in the two groups. These findings should be explained with caution because our study doesn’t provide the data associated with cancer-specific survival and recurrence.

**ARTICLE HIGHLIGHTS**

***Research background***

The first line treatment regimen for esophageal cancer is still surgical resection and the choice of surgical scheme depends on the surgeon.

***Research motivation***

Now the efficacy comparison of hybrid minimally invasive esophagectomy (HMIE) and open esophagectomy (OE) is still controversial.

***Research objectives***

To compare the perioperative and postoperative outcomes of HMIE and OE in patients with esophageal cancer.

***Research methods***

PubMed, EMBASE, and Cochrane Library databases were searched for related articles.

***Research results***

Seventeen studies including a total of 2397 patients were selected. HMIE was significantly associated with less blood loss (SMD = -0.43, 95%CI: -0.66, -0.20; *P* = 0.0002) and lower incidence of pulmonary complications (OR = 0.72, 95%CI: 0.57, 0.90; *P* = 0.004).

***Research conclusions***

Compared with OE, HMIE shows less blood loss and pulmonary complications.

***Research perspectives***

Further studies are necessary to evaluate the long-term oncologic outcomes of HMIE.

**REFERENCES**

1 **Howlader N**, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2013. National Cancer Institute. Bethesda, MD. Available from: URL: https://seer.cancer.gov/archive/csr/1975\_2013/

2 **Pennathur A**, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. *Lancet* 2013; **381**: 400-412 [PMID: 23374478 DOI: 10.1016/S0140-6736(12)60643-6]

3 **Mariette C**, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. *Lancet Oncol* 2007; **8**: 545-553 [PMID: 17540306 DOI: 10.1016/S1470-2045(07)70172-9]

4 **Cuschieri A**, Shimi S, Banting S. Endoscopic oesophagectomy through a right thoracoscopic approach. *J R Coll Surg Edinb* 1992; **37**: 7-11 [PMID: 1573620]

5 **van der Pas MH**, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC, Bonjer HJ; COlorectal cancer Laparoscopic or Open Resection II (COLOR II) Study Group. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. *Lancet Oncol* 2013; **14**: 210-218 [PMID: 23395398 DOI: 10.1016/S1470-2045(13)70016-0]

6 **Lacy AM**, García-Valdecasas JC, Delgado S, Castells A, Taurá P, Piqué JM, Visa J. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. *Lancet* 2002; **359**: 2224-2229 [PMID: 12103285 DOI: 10.1016/S0140-6736(02)09290-5]

7 **Kim W**, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Lee HJ; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). *Ann Surg* 2016; **263**: 28-35 [PMID: 26352529 DOI: 10.1097/SLA.0000000000001346]

8 **Mariette C**, Markar SR, Dabakuyo-Yonli TS, Meunier B, Pezet D, Collet D, D'Journo XB, Brigand C, Perniceni T, Carrère N, Mabrut JY, Msika S, Peschaud F, Prudhomme M, Bonnetain F, Piessen G; Fédération de Recherche en Chirurgie (FRENCH) and French Eso-Gastric Tumors (FREGAT) Working Group. Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer. *N Engl J Med* 2019; **380**: 152-162 [PMID: 30625052 DOI: 10.1056/NEJMoa1805101]

9 **Paireder M**, Asari R, Kristo I, Rieder E, Zacherl J, Kabon B, Fleischmann E, Schoppmann SF. Morbidity in open versus minimally invasive hybrid esophagectomy (MIOMIE): Long-term results of a randomized controlled clinical study. *Eur Surg* 2018; **50**: 249-255 [PMID: 30546384 DOI: 10.1007/s10353-018-0552-y]

10 **Parameswaran R**, Titcomb DR, Blencowe NS, Berrisford RG, Wajed SA, Streets CG, Hollowood AD, Krysztopik R, Barham CP, Blazeby JM. Assessment and comparison of recovery after open and minimally invasive esophagectomy for cancer: an exploratory study in two centers. *Ann Surg Oncol* 2013; **20**: 1970-1977 [PMID: 23306956 DOI: 10.1245/s10434-012-2848-7]

11 **Yun JS**, Na KJ, Song SY, Kim S, Jeong IS, Oh SG. Comparison of perioperative outcomes following hybrid minimally invasive versus open Ivor Lewis esophagectomy for esophageal cancer. *J Thorac Dis* 2017; **9**: 3097-3104 [PMID: 29221284 DOI: 10.21037/jtd.2017.08.49]

12 **Smithers BM**, Gotley DC, Martin I, Thomas JM. Comparison of the outcomes between open and minimally invasive esophagectomy. *Ann Surg* 2007; **245**: 232-240 [PMID: 17245176 DOI: 10.1097/01.sla.0000225093.58071.c6]

13 **Briez N**, Piessen G, Torres F, Lebuffe G, Triboulet JP, Mariette C. Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications. *Br J Surg* 2012; **99**: 1547-1553 [PMID: 23027071 DOI: 10.1002/bjs.8931]

14 **Scarpa M**, Cavallin F, Saadeh LM, Pinto E, Alfieri R, Cagol M, Da Roit A, Pizzolato E, Noaro G, Pozza G, Castoro C. Hybrid minimally invasive esophagectomy for cancer: impact on postoperative inflammatory and nutritional status. *Dis Esophagus* 2016; **29**: 1064-1070 [PMID: 26401634 DOI: 10.1111/dote.12418]

15 **Glatz T**, Marjanovic G, Kulemann B, Sick O, Hopt UT, Hoeppner J. Hybrid minimally invasive esophagectomy vs. open esophagectomy: a matched case analysis in 120 patients. *Langenbecks Arch Surg* 2017; **402**: 323-331 [PMID: 28083680 DOI: 10.1007/s00423-017-1550-4]

16 **Lee JM**, Cheng JW, Lin MT, Huang PM, Chen JS, Lee YC. Is there any benefit to incorporating a laparoscopic procedure into minimally invasive esophagectomy? The impact on perioperative results in patients with esophageal cancer. *World J Surg* 2011; **35**: 790-797 [PMID: 21327605 DOI: 10.1007/s00268-011-0955-4]

17 **Rinieri P**, Ouattara M, Brioude G, Loundou A, de Lesquen H, Trousse D, Doddoli C, Thomas PA, D'Journo XB. Long-term outcome of open versus hybrid minimally invasive Ivor Lewis oesophagectomy: a propensity score matched study. *Eur J Cardiothorac Surg* 2017; **51**: 223-229 [PMID: 28186271 DOI: 10.1093/ejcts/ezw273]

18 **Khan M**, Ashraf MI, Syed AA, Khattak S, Urooj N, Muzaffar A. Morbidity analysis in minimally invasive esophagectomy for oesophageal cancer versus conventional over the last 10 years, a single institution experience. *J Minim Access Surg* 2017; **13**: 192-199 [PMID: 28607286 DOI: 10.4103/0972-9941.199606]

19 **Findlay L**, Yao C, Bennett DH, Byrom R, Davies N. Non-inferiority of minimally invasive oesophagectomy: an 8-year retrospective case series. *Surg Endosc* 2017; **31**: 3681-3689 [PMID: 28078465 DOI: 10.1007/s00464-016-5406-8]

20 **Safranek PM**, Cubitt J, Booth MI, Dehn TC. Review of open and minimal access approaches to oesophagectomy for cancer. *Br J Surg* 2010; **97**: 1845-1853 [PMID: 20922782 DOI: 10.1002/bjs.7231]

21 **Shiraishi T**, Kawahara K, Shirakusa T, Yamamoto S, Maekawa T. Risk analysis in resection of thoracic esophageal cancer in the era of endoscopic surgery. *Ann Thorac Surg* 2006; **81**: 1083-1089 [PMID: 16488728 DOI: 10.1016/j.athoracsur.2005.08.057]

22 **Rolff HC**, Ambrus RB, Belmouhand M, Achiam MP, Wegmann M, Siemsen M, Kofoed SC, Svendsen LB. Robot-Assisted Hybrid Esophagectomy Is Associated with a Shorter Length of Stay Compared to Conventional Transthoracic Esophagectomy: A Retrospective Study. *Minim Invasive Surg* 2017; **2017**: 6907896 [PMID: 29362674 DOI: 10.1155/2017/6907896]

23 **Kubo N**, Ohira M, Yamashita Y, Sakurai K, Toyokawa T, Tanaka H, Muguruma K, Shibutani M, Yamazoe S, Kimura K, Nagahara H, Amano R, Ohtani H, Yashiro M, Maeda K, Hirakawa K. The impact of combined thoracoscopic and laparoscopic surgery on pulmonary complications after radical esophagectomy in patients with resectable esophageal cancer. *Anticancer Res* 2014; **34**: 2399-2404 [PMID: 24778050]

24 **Yanasoot A**, Yolsuriyanwong K, Ruangsin S, Laohawiriyakamol S, Sunpaweravong S. Costs and benefits of different methods of esophagectomy for esophageal cancer. *Asian Cardiovasc Thorac Ann* 2017; **25**: 513-517 [PMID: 28871799 DOI: 10.1177/0218492317731389]

25 **Sunpaweravong S**, Ruangsin S, Laohawiriyakamol S, Mahattanobon S, Geater A. Prediction of major postoperative complications and survival for locally advanced esophageal carcinoma patients. *Asian J Surg* 2012; **35**: 104-109 [PMID: 22884266 DOI: 10.1016/j.asjsur.2012.04.029]

26 **Maas KW**, Cuesta MA, van Berge Henegouwen MI, Roig J, Bonavina L, Rosman C, Gisbertz SS, Biere SS, van der Peet DL, Klinkenbijl JH, Hollmann MW, de Lange ES, Bonjer HJ. Quality of Life and Late Complications After Minimally Invasive Compared to Open Esophagectomy: Results of a Randomized Trial. *World J Surg* 2015; **39**: 1986-1993 [PMID: 26037024 DOI: 10.1007/s00268-015-3100-y]

27 **Rizk NP**, Ishwaran H, Rice TW, Chen LQ, Schipper PH, Kesler KA, Law S, Lerut TE, Reed CE, Salo JA, Scott WJ, Hofstetter WL, Watson TJ, Allen MS, Rusch VW, Blackstone EH. Optimum lymphadenectomy for esophageal cancer. *Ann Surg* 2010; **251**: 46-50 [PMID: 20032718 DOI: 10.1097/SLA.0b013e3181b2f6ee]

28 **Kang CH**, Kim YT, Jeon SH, Sung SW, Kim JH. Lymphadenectomy extent is closely related to long-term survival in esophageal cancer. *Eur J Cardiothorac Surg* 2007; **31**: 154-160 [PMID: 17145185 DOI: 10.1016/j.ejcts.2006.10.033]

29 **Martin DJ**, Church NG, Kennedy CW, Falk GL. Does systematic 2-field lymphadenectomy for esophageal malignancy offer a survival advantage? Results from 178 consecutive patients. *Dis Esophagus* 2008; **21**: 612-618 [PMID: 18459992 DOI: 10.1111/j.1442-2050.2008.00826.x]

30 **Peyre CG**, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, Hölscher A, Lerut T, Law S, Rice TW, Ruol A, van Lanschot JJ, Wong J, DeMeester TR. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. *Ann Surg* 2008; **248**: 549-556 [PMID: 18936567 DOI: 10.1097/SLA.0b013e318188c474]

31 **Espinoza-Mercado F**, Imai TA, Borgella JD, Sarkissian A, Serna-Gallegos D, Alban RF, Soukiasian HJ. Does the Approach Matter? Comparing Survival in Robotic, Minimally Invasive, and Open Esophagectomies. *Ann Thorac Surg* 2019; **107**: 378-385 [PMID: 30312615 DOI: 10.1016/j.athoracsur.2018.08.039]

32 **Naffouje SA**, Salloum RH, Khalaf Z, Salti GI. Outcomes of Open Versus Minimally Invasive Ivor-Lewis Esophagectomy for Cancer: A Propensity-Score Matched Analysis of NSQIP Database. *Ann Surg Oncol* 2019 [PMID: 30927192 DOI: 10.1245/s10434-019-07319-6]

33 **Xiong WL**, Li R, Lei HK, Jiang ZY. Comparison of outcomes between minimally invasive oesophagectomy and open oesophagectomy for oesophageal cancer. *ANZ J Surg* 2017; **87**: 165-170 [PMID: 26477880 DOI: 10.1111/ans.13334]

34 **Chen X**, Yang J, Peng J, Jiang H. Case-matched analysis of combined thoracoscopic-laparoscopic versus open esophagectomy for esophageal squamous cell carcinoma. *Int J Clin Exp Med* 2015; **8**: 13516-13523 [PMID: 26550289]

35 **Mu J**, Yuan Z, Zhang B, Li N, Lyu F, Mao Y, Xue Q, Gao S, Zhao J, Wang D, Li Z, Gao Y, Zhang L, Huang J, Shao K, Feng F, Zhao L, Li J, Cheng G, Sun K, He J. Comparative study of minimally invasive versus open esophagectomy for esophageal cancer in a single cancer center. *Chin Med J (Engl)* 2014; **127**: 747-752 [PMID: 24534234 DOI: 10.3760/cma.j.issn.0366-6999.20132224]

36 **Biere SS**, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, Gisbertz SS, Klinkenbijl JH, Hollmann MW, de Lange ES, Bonjer HJ, van der Peet DL, Cuesta MA. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. *Lancet* 2012; **379**: 1887-1892 [PMID: 22552194 DOI: 10.1016/S0140-6736(12)60516-9]

37 **Markar S**, Gronnier C, Duhamel A, Mabrut JY, Bail JP, Carrere N, Lefevre JH, Brigand C, Vaillant JC, Adham M, Msika S, Demartines N, Nakadi IE, Meunier B, Collet D, Mariette C; FREGAT (French Eso-Gastric Tumors) working group, FRENCH (Fédération de Recherche EN CHirurgie), and AFC (Association Française de Chirurgie). The Impact of Severe Anastomotic Leak on Long-term Survival and Cancer Recurrence After Surgical Resection for Esophageal Malignancy. *Ann Surg* 2015; **262**: 972-980 [PMID: 26469952 DOI: 10.1097/SLA.0000000000001011]

38 **Rutegård M**, Lagergren P, Rouvelas I, Mason R, Lagergren J. Surgical complications and long-term survival after esophagectomy for cancer in a nationwide Swedish cohort study. *Eur J Surg Oncol* 2012; **38**: 555-561 [PMID: 22483704 DOI: 10.1016/j.ejso.2012.02.177]

39 **Aahlin EK**, Olsen F, Uleberg B, Jacobsen BK, Lassen K. Major postoperative complications are associated with impaired long-term survival after gastro-esophageal and pancreatic cancer surgery: a complete national cohort study. *BMC Surg* 2016; **16**: 32 [PMID: 27193578 DOI: 10.1186/s12893-016-0149-y]

40 **Qi W**, Zixiang W, Tianwei Z, Shuai F, Sai Z, Gang S, Ming W. Long-term outcomes of 530 esophageal squamous cell carcinoma patients with minimally invasive Ivor Lewis esophagectomy. *J Surg Oncol* 2018; **117**: 957-969 [PMID: 29878389 DOI: 10.1002/jso.24997]

41 **Wang H**, Shen Y, Feng M, Zhang Y, Jiang W, Xu S, Tan L, Wang Q. Outcomes, quality of life, and survival after esophagectomy for squamous cell carcinoma: A propensity score-matched comparison of operative approaches. *J Thorac Cardiovasc Surg* 2015; **149**: 1006-14; discussion 1014- 5.e4 [PMID: 25752374 DOI: 10.1016/j.jtcvs.2014.12.063]

**P-Reviewer:** Ahmed M, Chiu KW, Chen XZ, Shimizu Y **S-Editor:** Ji FF **L-Editor:** Wang TQ **E-Editor:** Liu MY

**Specialty type:** Oncology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0

Total manuscripts identified from databases (*n* = 866)

Excluding

211 duplicates

Abstracts and titles read for further screening

(*n* = 655)

Irrelevant articles

removed (*n* = 596)

Full-text articles evaluated for eligibility (*n* = 59)

Excluding 42 articles according to the eligibility criteria

Studies left for the meta-analysis (*n* = 17)

**Figure 1 Flow diagram showing the selection process of relevant literature.**



**Figure 2 Funnel plots of eligible studies.** A: Incidence of pulmonary complications; B: Incidence of cardiac complications; C: Incidence of anastomotic leak; D: Total mortality.

**Table 1 Baseline characteristics of the eligible studies**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Time** | **Design** | **Area** | **Male/total** | **Age** | **Weight (kg/BMI)** |
| **HMIE** | **OE** | **HMIE** | **OE** | **HMIE** | **OE** |
| Yun *et al*[11] | 2017 | Retrospective | South Korea | 51/53 | 61/62 | 6648-83 | 6845-79 | NA | NA |
| Scarpa *et al*[14] | 2015 | Retrospective | Italy | 25/34 | 27/34 | 6252-70 | 6456-70 | NA | NA |
| Briez *et al*[13] | 2012 | Retrospective | France | 110/140 | 117/140 | NA | NA | NA | NA |
| Mariette *et al*[8] | 2019 | RCT | France | 88/103 | 87/104 | 5923-75 | 6241-78 | 2616-37 | 2518-35 |
| Glatz *et al*[15] | 2017 | Retrospective | Germany | 49/60 | 52/60 | 6142-92 | 6144-84 | 2719-40 | 2617-38 |
| Rinieri *et al*[17] | 2016 | Retrospective | France | 59/70 | 54/70 | 61.1 ± 9 | 61 ± 9 | NA | NA |
| Paireder *et al*[9] | 2018 | RCT | Austria | 10/14 | 10/12 | 64.540-75 | 62.549-77 | 24.0818.07-41.45 | 26.9617.53-35.26 |
| Rolff *et al*[22] | 2017 | Retrospective | Denmark | 50/56 | 125/160 | 6639-86 | 6528-88 | 25.818.8-31.2 | 26.615.6-43.7 |
| Parameswaran *et al*[10] | 2013 | Prospective | United Kingdom | 23/31 | 15/19 | 6748-79 | 6451-77 | NA | NA |
| Smithers *et al*[12] | 2007 | Prospective | Australia | 247/309 | 104/114 | 6427-85 | 62.529-81 | 8041-132 | 78.540-119 |
| Lee *et al*[16] | 2011 | Prospective | Taiwan | 43/44 | 61/64 | 59.744-78 | 56.5830-90 | NA | NA |
| Findlay *et al*[19] | 2016 | Retrospective | United States | 84/95 | 69/87 | 67.76 | 65.54 | NA | NA |
| Safranek *et al*[20] | 2010 | Prospective | United Kingdom | 28/34 | 38/46 | 6344-76 | 6044-77 | NA | NA |
| Shiraishi *et al*[21] | 2006 | Retrospective | Japan | 32/38 | 31/37 | 62.1 ± 9 | 66.5 ± 9.3 | NA | NA |
| Kubo *et al*[23] | 2014 | Retrospective | Japan | 34/42 | 60/74 | 65.4 ± 9 | 62.2 ± 7.2 | NA | NA |
| Yanasoot *et al*[24] | 2017 | Retrospective | Thailand | 13/16 | 46/54 | 58.19± 7.78 | 61.02± 8.59 | NA | NA |
| Khan *et al*[18] | 2017 | Retrospective | Pakistan | 17/31 | 52/90 | 48.7 ± 13.1 | 56.5 ± 10.7 | 22.315-30.8 | 21.615-35 |

NA: Not available; HMIE: Hybrid minimally invasive esophagectomy; OE: Open esophagectomy.

**Table 2 Baseline characteristics**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Tumor location** | **Histological subtype** | **Pathological stage** | **ASA risk score** |
| **Upper/Middle/ Lower** | **ACA/SCC** | **0-I-II/ III-IV** | **1/2/3** |
| **HMIE** | **OE** | **HMIE** | **OE** | **HMIE** | **OE** | **HMIE** | **OE** |
| Yun *et al*[11] | 0/18/35 | 0/18/44 | NA | NA | 48/5 | 45/17 | NA | NA |
| Scarpa *et al*[14] | 0/25/9 | 0/29/5 | 24/10 | 24/10 | 29/5 | 29/5 | 5/22/7 | 4/17/13 |
| Briez *et al*[13] | 0/54/86 | 0/56/84 | 57/83 | 57/83 | 92/48 | 89/51 | 20/102/18 | 22/94/24 |
| Mariette *et al*[8] | 0/32/71 | 1/31/72 | 57/46 | 66/38 | 48/50 | 52/48 | 25/61/17 | 34/58/12 |
| Glatz *et al*[15] | 0/8/52 | 0/8/52 | 46/14 | 47/13 | 44/15 | 41/19 | NA | NA |
| Rinieri *et al*[17] | 60/10/0 | 63/7/0 | 50/20 | 55/15 | 52/18 | 49/21 | 9/48/13 | 14/40/16 |
| Paireder *et al*[9] | NA | NA | 10/4 | 11/1 | 7/7 | 8/4 | NA | NA |
| Rolff *et al*[22] | NA | NA | NA | NA | NA | NA | 17/28/12 | 41/80/39 |
| Parameswaran *et al*[10] | NA | NA | 27/3 | 16/3 | 18/31 | 8/11 | NA | NA |
| Smithers *et al*[12] | 8/68/208 | 0/3/47 | 199/74 | 100/7 | 183/108 | 36/75 | 12/200/98 | 6/68/38 |
| Lee *et al*[16] | 2/34/8 | 9/46/9 | 1/43 | 5/59 | 39/6 | 49/15 | NA | NA |
| Findlay *et al*[19] | NA | NA | NA | NA | NA | NA | NA | NA |
| Safranek *et al*[20] | 0/1/24 | 0/1/20 | 29/3 | 43/3 | 18/16 | 17/29 | NA | NA |
| Shiraishi *et al*[21] | NA | NA | NA | NA | NA | NA | NA | NA |
| Kubo *et al*[23] | 8/21/13 | 3/36/34 | NA | NA | 28/14 | 41/33 | NA | NA |
| Yanasoot *et al*[24] | 2/8/6 | 11/28/15 | 1/15 | 5/49 | 6/10 | 19/35 | NA | A |
| Khan *et al*[18] | NA | NA | 28/3 | 65/25 | 4/91 | 5/83 | NA | NA |

NA: Not available; ACA: Adenocarcinoma; SCC: Squamous cell carcinoma; ASA: American Society of Anesthesilogists; HMIE: Hybrid minimally invasive esophagectomy; OE: Open esophagectomy.

**Table 3 Quality assessment of the eligible studies: Newcastle-Ottawa Scale for case control studies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Selection** | **Comparability** | **Exposure** | **Total Score** |
| **1** | **2** | **3** | **4** | **5** | **6** | **7** | **8** |
| Parameswaran *et al*[10] | Y | Y | Y | Y | Y | Y | Y | Y | 8 |
| Yun *et al*[11] | Y | Y | Y | Y | Y | Y |  |  | 6 |
| Smithers *et al*[12] | Y | Y | Y | Y | Y | Y | Y |  | 7 |
| Briez *et al*[13] | Y | Y | Y | Y | Y | Y | Y |  | 7 |
| Scarpa *et al*[14] | Y | Y | Y | Y | Y | Y |  |  | 6 |
| Glatz *et al*[15] | Y | Y | Y | Y | Y | Y |  |  | 6 |
| Lee *et al*[16] | Y | Y | Y | Y | Y | Y | Y |  | 7 |
| Rinieri *et al*[17] | Y | Y | Y | Y | Y | Y | Y |  | 7 |
| Khan *et al*[18] | Y | Y | Y | Y | Y | Y |  |  | 6 |
| Findlay *et al*[19] | Y | Y | Y | Y | Y | Y | Y |  | 7 |
| Safranek *et al*[20] | Y | Y | Y | Y | Y | Y |  |  | 6 |
| Shiraishi *et al*[21] | Y | Y | Y | Y | Y | Y |  |  | 6 |
| Rolff *et al*[22] | Y | Y | Y | Y | Y | Y |  |  | 6 |
| Yanasoot *et al*[24] | Y | Y | Y | Y | Y | Y |  |  | 6 |
| Kubo *et al*[23] | Y | Y | Y | Y | Y | Y |  |  | 6 |

1: Is the case definition adequate; 2: Representativeness of the cases; 3: Selection of controls; 4: Definition of controls; 5: Comparability of cases and controls on the basis of the design or analysis; 6: Assessment of exposure; 7: Same method of ascertainment for cases and controls; 8: Non-response rate; Y: Yes.

**Table 4 Quality assessment of the eligible studies: Risk bias of Cochrane Collaboration tool for randomized controlled trials**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Random sequence** **generation** | **Allocation****concealment** | **Blinding of participants and personnel** | **Blinding of outcome****assessment** | **Incomplete****outcome data** | **Selective reporting** | **Other bias** |
| Paireder *et al*[9] | Low risk | High risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear risk |
| Mariette *et al*[8] | Low risk | Low risk | Low risk | High risk | Unclear risk | Unclear risk | Unclear risk |

**Table 5 Comparison of perioperative outcomes between hybrid minimally invasive esophagectomy and open esophagectomy groups**

|  |  |  |
| --- | --- | --- |
| **Perioperative outcomes** | **SMD and 95%CI** | ***P*-value** |
| Lymph node yield | Total HMIE *vs* OE | 0.11 (-0.08, 0.30) | 0.26 |
|  | HMIE with A *vs* OE | 0.19 (-0.00, 0.37) | 0.05 |
| Blood loss | Total HMIE *vs* OE | -0.43 (-0.66, -0.20) | 0.0002 |
|  | HMIE with A *vs* OE | -0.51 (-0.74, -0.27) | <0.0001 |
| Operative time | Total HMIE *vs* OE | 0.24 (-0.14, 0.61) | 0.22 |
|  | HMIE with A *vs* OE | 0.1 (-0.33, 0.52) | 0.65 |

A: Laparoscopy and thoracotomy; SMD: Standard mean difference; CI: Confidence interval; HMIE; Hybrid minimally invasive esophagectomy; OE: Open esophagectomy.

**Table 6 Postoperative outcomes between hybrid minimally invasive esophagectomy group and open esophagectomy groups**

|  |  |  |
| --- | --- | --- |
| **Postoperative outcomes** | **OR or SMD, 95%CI** | ***P-*value** |
| ICU stay | Total HMIE *vs* OE | -0.01 (-0.21, 0.19) | 0.93 |
| HMIE with A *vs* OE | -0.05 (-0.37, 0.27) | 0.76 |
| Hospital stay | Total HMIE *vs* OE | -0.13 (-0.28, 0.01) | 0.08 |
| HMIE with A *vs* OE | -0.37 (-0.64, -0.09) | 0.009 |
| Total complications | Total HMIE *vs* OE | 0.68 (0.46, 0.99) | 0.05 |
| HMIE with A *vs* OE | 0.62 (0.41, 0.94) | 0.02 |
| Pulmonary complications | Total HMIE *vs* OE | 0.72 (0.57, 0.90) | 0.004 |
| HMIE with A *vs* OE | 0.69 (0.53, 0.90) | 0.005 |
| Cardiac complications | Total HMIE *vs* OE | 0.91 (0.62, 1.34) | 0.64 |
| HMIE with A *vs* OE | 0.97 (0.65, 1.43) | 0.86 |
| Anastomotic leak | Total HMIE *vs* OE | 0.95 (0.67, 1.35) | 0.78 |
| HMIE with A *vs* OE | 0.99 (0.67, 1.46) | 0.96 |
| Total mortality | Total HMIE *vs* OE | 0.7 (0.47, 1.06) | 0.09 |
| HMIE with A *vs* OE | 0.65 (0.4, 1.07) | 0.09 |
| 30-d mortality | Total HMIE *vs* OE | 1.00 (0.45, 2.23) | 0.99 |
| HMIE with A *vs* OE | 1.10 (0.47, 2.59) | 0.82 |
| 90-d mortality | Total HMIE *vs* OE | 0.80 (0.43, 1.48) | 0.47 |
| HMIE with A *vs* OE | 0.80 (0.43, 1.48) | 0.47 |

A: Laparoscopy and thoracotomy; OR: Odds ratio; SMD: Standard mean difference; CI: Confidence interval; ICU: Intensive care unit; HMIE; Hybrid minimally invasive esophagectomy; OE: Open esophagectomy.